Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE 80 25 versus ORVATEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERIDE 80 25 versus ORVATEN.
INDERIDE-80/25 vs ORVATEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
INDERIDE-80/25 is a combination of propranolol (a non-selective beta-adrenergic receptor antagonist) and hydrochlorothiazide (a thiazide diuretic). Propranolol blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and renin release, thereby lowering blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the kidney, increasing excretion of sodium, chloride, and water, reducing plasma volume.
Orvaten is a purified form of tetrahydrobiopterin (BH4), a cofactor for aromatic amino acid hydroxylases including phenylalanine hydroxylase (PAH), tyrosine hydroxylase, and tryptophan hydroxylase. In patients with phenylketonuria (PKU), it enhances the activity of residual PAH, leading to increased metabolism of phenylalanine and reduced blood phenylalanine levels.
One tablet (80 mg propranolol/25 mg hydrochlorothiazide) orally twice daily.
5 mg orally twice daily
None Documented
None Documented
Propranolol: 3-6 hours (single dose), prolonged with chronic dosing (up to 12 hours). Hydrochlorothiazide: 6-15 hours; prolonged in renal impairment.
Terminal half-life: 8-12 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment necessitates dose adjustment.
Renal: 40% unchanged propranolol; 60% as metabolites. Biliary/fecal: minimal (less than 1%). Hydrochlorothiazide: renal 95% unchanged.
Renal: 60% unchanged; Biliary/fecal: 30% as metabolites; 10% exhaled as CO2.
Category C
Category C
Beta Blocker and Thiazide Diuretic
Beta Blocker